Long-term off-label dupilumab in pediatric atopic dermatitis: A case series

Alison D. Treister, Peter A Lio

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background/Objectives: Clinical trials of dupilumab have shown efficacy in treating moderate-to-severe atopic dermatitis (AD) in adult patients. While a phase 2 trial of dupilumab has shown efficacy and safety in children, the medication awaits Food and Drug Administration (FDA) approval, and off-label use is limited by dosing currently available to adults. We present this case series to describe the efficacy and safety profile of off-label dupilumab use in six pediatric patients treated by one provider in a private practice. Methods: We conducted a retrospective chart review of all patients under the age of 18 receiving dupilumab for AD. Two dosing regimens were used as follows: adult dose for patients ≥ 40 kg and half dose for those < 40 kg. We recorded the investigator's global assessment (IGA) and body surface area (BSA) prior to dupilumab initiation and following treatment. All patients were warned of potential side effects including injection site reaction, conjunctivitis, increased risk of infection, and lack of information about use in children. Results: Six pediatric patients were identified with an average age of 10.8 years (range: 7-15). All patients had a decrease in IGA of at least 2 points using biweekly 300 or 150 milligram (mg) doses for an average treatment duration of 8.5 months (range: 6-11). Three patients (50%) had an IGA of 1 after treatment. No side effects were reported. Conclusions: Dupilumab appears to be an effective treatment for AD in pediatric patients. Optimal dose and delivery have yet to be determined.

Original languageEnglish (US)
Pages (from-to)85-88
Number of pages4
JournalPediatric dermatology
Volume36
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Atopic Dermatitis
Pediatrics
Off-Label Use
Research Personnel
Drug Approval
Safety
SAR231893
Conjunctivitis
Private Practice
Body Surface Area
United States Food and Drug Administration
Therapeutics
Clinical Trials
Injections
Infection

Keywords

  • atopic dermatitis
  • therapy-systemic

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Dermatology

Cite this

@article{798e7a1dbbba46589cc4b07fd440ab5c,
title = "Long-term off-label dupilumab in pediatric atopic dermatitis: A case series",
abstract = "Background/Objectives: Clinical trials of dupilumab have shown efficacy in treating moderate-to-severe atopic dermatitis (AD) in adult patients. While a phase 2 trial of dupilumab has shown efficacy and safety in children, the medication awaits Food and Drug Administration (FDA) approval, and off-label use is limited by dosing currently available to adults. We present this case series to describe the efficacy and safety profile of off-label dupilumab use in six pediatric patients treated by one provider in a private practice. Methods: We conducted a retrospective chart review of all patients under the age of 18 receiving dupilumab for AD. Two dosing regimens were used as follows: adult dose for patients ≥ 40 kg and half dose for those < 40 kg. We recorded the investigator's global assessment (IGA) and body surface area (BSA) prior to dupilumab initiation and following treatment. All patients were warned of potential side effects including injection site reaction, conjunctivitis, increased risk of infection, and lack of information about use in children. Results: Six pediatric patients were identified with an average age of 10.8 years (range: 7-15). All patients had a decrease in IGA of at least 2 points using biweekly 300 or 150 milligram (mg) doses for an average treatment duration of 8.5 months (range: 6-11). Three patients (50{\%}) had an IGA of 1 after treatment. No side effects were reported. Conclusions: Dupilumab appears to be an effective treatment for AD in pediatric patients. Optimal dose and delivery have yet to be determined.",
keywords = "atopic dermatitis, therapy-systemic",
author = "Treister, {Alison D.} and Lio, {Peter A}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/pde.13697",
language = "English (US)",
volume = "36",
pages = "85--88",
journal = "Pediatric Dermatology",
issn = "0736-8046",
publisher = "Wiley-Blackwell",
number = "1",

}

Long-term off-label dupilumab in pediatric atopic dermatitis : A case series. / Treister, Alison D.; Lio, Peter A.

In: Pediatric dermatology, Vol. 36, No. 1, 01.01.2019, p. 85-88.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term off-label dupilumab in pediatric atopic dermatitis

T2 - A case series

AU - Treister, Alison D.

AU - Lio, Peter A

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background/Objectives: Clinical trials of dupilumab have shown efficacy in treating moderate-to-severe atopic dermatitis (AD) in adult patients. While a phase 2 trial of dupilumab has shown efficacy and safety in children, the medication awaits Food and Drug Administration (FDA) approval, and off-label use is limited by dosing currently available to adults. We present this case series to describe the efficacy and safety profile of off-label dupilumab use in six pediatric patients treated by one provider in a private practice. Methods: We conducted a retrospective chart review of all patients under the age of 18 receiving dupilumab for AD. Two dosing regimens were used as follows: adult dose for patients ≥ 40 kg and half dose for those < 40 kg. We recorded the investigator's global assessment (IGA) and body surface area (BSA) prior to dupilumab initiation and following treatment. All patients were warned of potential side effects including injection site reaction, conjunctivitis, increased risk of infection, and lack of information about use in children. Results: Six pediatric patients were identified with an average age of 10.8 years (range: 7-15). All patients had a decrease in IGA of at least 2 points using biweekly 300 or 150 milligram (mg) doses for an average treatment duration of 8.5 months (range: 6-11). Three patients (50%) had an IGA of 1 after treatment. No side effects were reported. Conclusions: Dupilumab appears to be an effective treatment for AD in pediatric patients. Optimal dose and delivery have yet to be determined.

AB - Background/Objectives: Clinical trials of dupilumab have shown efficacy in treating moderate-to-severe atopic dermatitis (AD) in adult patients. While a phase 2 trial of dupilumab has shown efficacy and safety in children, the medication awaits Food and Drug Administration (FDA) approval, and off-label use is limited by dosing currently available to adults. We present this case series to describe the efficacy and safety profile of off-label dupilumab use in six pediatric patients treated by one provider in a private practice. Methods: We conducted a retrospective chart review of all patients under the age of 18 receiving dupilumab for AD. Two dosing regimens were used as follows: adult dose for patients ≥ 40 kg and half dose for those < 40 kg. We recorded the investigator's global assessment (IGA) and body surface area (BSA) prior to dupilumab initiation and following treatment. All patients were warned of potential side effects including injection site reaction, conjunctivitis, increased risk of infection, and lack of information about use in children. Results: Six pediatric patients were identified with an average age of 10.8 years (range: 7-15). All patients had a decrease in IGA of at least 2 points using biweekly 300 or 150 milligram (mg) doses for an average treatment duration of 8.5 months (range: 6-11). Three patients (50%) had an IGA of 1 after treatment. No side effects were reported. Conclusions: Dupilumab appears to be an effective treatment for AD in pediatric patients. Optimal dose and delivery have yet to be determined.

KW - atopic dermatitis

KW - therapy-systemic

UR - http://www.scopus.com/inward/record.url?scp=85055277629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055277629&partnerID=8YFLogxK

U2 - 10.1111/pde.13697

DO - 10.1111/pde.13697

M3 - Article

VL - 36

SP - 85

EP - 88

JO - Pediatric Dermatology

JF - Pediatric Dermatology

SN - 0736-8046

IS - 1

ER -